Immunome Inc. (IMNM) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
the bull case· 4
5
disclosed supplier and customer ties in SEC filings
sec filingsedgar4
of the funds on file reporting a position in IMNM
n-portas of Jun 30 '26+5.47%
change in shares held by the ten largest reporting managers
13fJun 30 '26203
managers reporting a position in thirteen F filings
13fJun 30 '26the bear case· 2
6 of 24
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '260.59%
of State Street SPDR S P Biotech ETF assets as the largest fund weight
n-portJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 12 '26 report. Not a forecast, not advice.
IMNM (Immunome Inc.) has 4 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
Of the 6 companies Immunome Inc. moves with most closely, none share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
tall tick = annual report · 1 on record
203 managers report a position worth $2.5B between them, and 19 of them hold 80% of it.
Immunome Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 23.98 at 3:45 pm ET, low 23.42 at 10:00 am ET.